AIM: Although melanin-concentrating hormone (MCH) is believed to be an important regulator of feeding behavior, both its acute and chronic effects on food intake as well as its interaction with other brain peptides involved in the control of appetite remain unclear. Therefore, the acute effects of MCH on food intake and the chronic effect of MCH on food intake and the gene expression of various hypothalamic peptides involved in the control of appetite were studied in rats. METHODS AND RESULTS: Either the acute or the continuous intraventricular infusion of MCH for 12 days stimulated feeding in both Wistar or Sprague -Dawley rats. Removal of the hypothalamus at the end of the chronic infusion studies allowed measurement of the expression of mRNAs encoding for MCH, neuropeptide Y (NPY), orexin, agouti gene-related peptide, cocaine and amphetamine-related transcript and neurotensin -neuropeptides involved in the control of appetite. Chronic intraventricular infusion of MCH activated only NPY mRNA synthesis in Sprague -Dawley rats. The increase in food intake in response to MCH in Sprague -Dawley rats did not appear to be due to the release of NPY since combination studies demonstrated consistently additive effects of the two peptides on food intake at maximum or near maximum doses. CONCLUSIONS: These results strongly suggest that MCH is an orexigenic peptide involved in the control of both short-and long term food intake in satiated rats and further indicate that the MCH pathway is a possible target for the control of food intake and obesity.
Introduction
Melanin-concentrating hormone (MCH) is a peptide located in the lateral hypothalamus which appears to play an important role in the control of food intake and energy balance. 1 -5 For example, injection of relatively high doses of MCH ( ! 5 mg=rat) into the ventricular system of the brain stimulates food intake in free feeding rats. 6 -8 Lower doses of MCH also increase food intake when injected directly into the paraventricular nucleus (0.5 mg=rat). 9 In addition, MCH mRNA is increased in the hypothalamus of ob=ob mice and after fasting in rats -both models of hyperphagia. 7, 10 Finally, knockout of MCH production in mice produces an animal which is hypophagic and lean while overexpression of MCH in the lateral hypothalamus leads to increased food intake and obesity in this rodent species. 4, 11 Collectively, these observations suggest that endogenous MCH in the brain functions to enhance appetite and possibly also acts to reduce energy expenditure.
In contrast to these findings, repeated single injections of MCH into the brain produce increased food intake only for the first few days of administration without change in body weight. 6 Furthermore, both intracerebroventricular and intra-hypothalamic injections of low doses (1 -100 ng) of MCH have been shown to reduce food intake in free-feeding rats. 10 Taken together, these results do not present a clear and consistent picture of the effects of MCH on food intake.
Since feeding behavior is mediated by a complex interplay between neural pathways, feeding stimuli often produce changes in the release of orexigenic and anorectic neurotransmitters in the brain. 12 -14 Consequently, food intake in response to a given stimuli may be mediated by the coordinated activity of a variety of neural pathways which may also influence other aspects of hypothalamic function. 12, 15 Several studies have shown MCH to have an interaction with other peptides in the brain. For example, MCH-induced food intake can be prevented when co-injected with a variety of anorectic peptides, while lower levels of MCH have been found in the brain of M3 muscarinic receptor knockout mice. 16, 17 However, the changes in endogenous peptides and neurotransmitters which may contribute to the effect of MCH on food intake and other aspects of hypothalamic function have not been clearly defined.
In consequence, these studies had two major aims. Firstly, to determine the acute and chronic effects of central administration of MCH on food intake and body weight in rats and, secondly, to identify changes in hypothalamic peptides through which the changes in food intake and body weight induced by chronic infusion of MCH may occur.
Methods

Animals
These studies were conducted with both male Wistar and male Sprague -Dawley rats weighing between 310 and 370 g (age 8 -11 weeks, Charles River, St Aubin-les-Elbeuf, France). All animals were maintained on a 12 h=12 h light=dark cycle (lights on at 7.30 am) at 22 AE 3 C and 55% relative humidity and were supplied with food in the form of 6 mm pellets (Type A03, Usine Alimentation Rationelle, Epinay-Sur-Orge, France) with tap water available ad-libitum. The food had the following dry weight composition: 64% carbohydrate, 22% protein, 4.3% fat, 4% cellulose and 5.5% ash. All animal procedures complied with French laws regarding animal experimentation (Decree no. 87-848, 19 October 1987 and the Ministerial Decree of 19 April 1988) and were preapproved by the ethical committee of the Servier Research Institute.
Intracerebroventicular cannula implantation
Rats were anesthetized with sodium pentobarbital (60 mg=kg, i.p.) and their heads placed into a stereotaxic device (David Kopf, Phymep, France). Stainless steel guide cannula (Plastics One Inc. Phymep, France for acute studies or Alzet brain infusion kits, Charles River, Palo Alto, CA, USA for chronic studies) were then implanted into the right lateral ventricle according to the following coordinates: AP ¼ 7 0.8 mm, L ¼ 7 1.2 mm and V ¼ 7 3.5 mm to bregma. After implantation, each cannula was closed with a stainless steel obturator and kept in place with dental cement (Kulzer=Heraeus, Dormagen, Germany). During the following 7 day recovery period, the animals were housed individually and handled daily to minimize non-specific stress.
Central peptide administration
Acute experiments. On the day of study the animals were lightly anesthetized with Forene 1 (Abbott, France). Thereafter, peptide solutions were infused slowly into the right lateral ventricle over a 30 s period (final volume administered 2.5 ml).
Chronic experiments. Peptides were infused into the right lateral ventricle using osmotic mini pumps (Alzet model 2002). The osmotic pumps were placed under the dorsal skin of the neck and connected to the intracerebroventricular (i.c.v.) cannula using plastic tubing (length 9 cm; i.d. 0.69 mmÂOD 1.14 mm). At the start of the study each cannula was filled with artificial CSF.
Feeding studies
Acute experiments. The animals were distributed into matched experimental and control groups and then injected i.c.v. with either artificial CSF or peptides in artificial CSF. The injections were performed at 9.00 am, shortly after the beginning of the light phase. After injection the animals were returned to their home cage which contained a known weight of food pellets contained in a spill-free cup. At different times during the test period, the food container was briefly removed and weighed to determine quantity of food consumed. Each food intake measurement was corrected for spillage.
Chronic experiments. After distribution into matched experimental and control groups, the rats were infused either with artificial CSF (0.5 ml=h) or MCH (8 mg=rat=day). Body weight and food intake were then recorded daily for 12 days.
At the end of all experiments, the animals were euthanized and the position of the ventricular cannula assessed following the injection of 150 ml of Evans blue dye (2 mg=ml) and visual examination of brain slices. Only parameters recorded from animals with correctly positioned cannulas were included in the results. After checking cannula placement, the hypothalamus was dissected from the animals chronically infused with MCH according to the boundaries defined by Glowinsky and Iversen 18 and stored frozen at 7 80 C until used for later RNA extraction.
RNA extraction and semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from the hypothalamus of both control and MCH-treated rats using a modification of the acid guanidium -thiocyanate -phenol chloroform method. 19 RNA quality was monitored by optical density (260 nm=280 nm ratio) and by ethidium bromide staining of 0.8% agarose gels after electrophoresis.
A relative estimate of specific neuropeptide-encoding mRNA variations in control and MCH-injected rats was Administration of melanin-concentrating hormone O Della-Zuana et al performed using RT-PCR as described below. The technique was standardized with respect to the endogenous ubiquitous mRNA encoding for GAPDH. This mRNA was co-reversetranscribed and co-amplified in the same reaction as the analyzed transcripts. The RT was performed with 1 mg of hypothalamic RNA, 15 -17 mer oligo-d(T) primers and AMV reverse transcriptase according to standard protocols. The PCR was performed in a 30 ml reaction solution containing 1ÂPCR buffer (Appligene, France), 200 mM deoxy NTPS, 2 mCi of 33 P-dCTP (Amersham, UK), 1 mM each of specific primers, 0.2 U Taq polymerase (Appligene, France) and 2 ml of a 10-fold dilution of the RT mixture. The PCR profile first involved heating at 94 C for 3 min and then passage through various cycles of amplification depending on the pair of primers ( Table 1 ). The profile was as follows: 50 s at 94 C (denaturation), 50 s at 52 C (annealing) and 50 s at 72 C (extension). A final extension of 7 min at 72 C was performed. Samples of the PCR products (10 -20 ml of the PCR mixture) were separated by electrophoresis on a 0.8 -1.2% agarose gel which was then dried and exposed to X-ray film. Quantitative densitometric analysis was performed using a computerized image analysis system (Bioimaging analyzer, BAS-1500, Fuji Film).
In preliminary experiments, kinetics and yield of amplification were checked for each pair of primers and final conditions were established in order to stay within the exponential phase. As controls, the primers were chosen from different exons to distinguish the cDNA amplification from contaminating genomic DNA. PCR was performed with non-reversed transcribed RNA in order to reveal putative cDNA contamination. Only RNA samples with correct controls were included in the results. 
Materials
Results
Changes in food intake after acute central administration of MCH to Wistar and Sprague -Dawley rats (Figure 1) The results demonstrate that doses of 1, 5 and 10 mg MCH significantly stimulated food intake in satiated Wistar rats whereas lower doses were ineffective ( Figure 1A ). The increase in food intake was apparent after 1 h and for all doses had reached a maximum relative to control values 2 h after injection. Twenty-four hours after treatment there was no significant difference in food intake between control and MCH-injected rats (results not shown).
When MCH was administered to Sprague -Dawley rats the increase in food intake reached statistical significance only at the two highest doses administered (5 and 10 mg - Figure  1A ). While Sprague -Dawley rats were apparently less sensitive to MCH the maximum developed response to the peptide was similar between the two rat strains.
NPY produced a dose-related increase in food intake in both Sprague -Dawley and Wistar rats -reaching a maximum effect at a dose of 5 mg ( Figure 1B) . In both rat strains NPY produced a greater maximal increase in food intake than did MCH. Administration of melanin-concentrating hormone O Della-Zuana et al
Changes in food intake, body weight and neuropeptide gene expression following chronic administration of MCH to rats Constant infusion of MCH (8 mg=rat=day) into the brain for 12 days produced a significant increase in food intake in both Sprague -Dawley and Wistar rats (Figure 2 ). The increase in food intake in Sprague -Dawley rats after 12 days of infusion was significantly greater than in Wistar rats (9.79 AE 0.79 vs 6.81 AE 1.0, P < 0.05). Although MCH produced a significantly greater increase in food intake in Sprague -Dawley rats, the associated increase in body weight did not differ significantly between the two strains (66.64 AE 4.34 vs 66.38 AE 4.29, P ¼ NS). At the end of the treatment period, the hypothalamus was removed from each rat and the gene expression of various peptides involved in food intake was determined. The results demonstrate significant differences in hypothalamic MCH and NPY mRNA levels between the control rats of both strains, whereas the other neuropeptide mRNA levels measured were not significantly influenced by genotype ( Figure  3 ). After infusion of MCH the only change noted was a small but statistically significant increase in the expression of NPY mRNA in Sprague -Dawley rats ( Table 2) .
Effect of MCH and NPY alone and in combination on food intake
The relationship between MCH and NPY in Sprague -Dawley rats was next explored in a series of co-injection studies. The results show the feeding responses to threshold (0.5 mg), intermediate (1 mg) and maximum (5 mg) doses of MCH and NPY (Figure 4) . At every dose studied the combination of NPY and MCH administered at the same dose produced a significantly greater stimulation of food intake than either peptide administered alone. When administered at threshold doses (0.5 mg) the combination of MCH and NPY resulted in a potentiated effect on food intake moving progressively Statistics were by one-way ANOVA followed by the Newman -Keuls test at each time point: s P < 0.05 -0.5 mg group vs control group; *P < 0.05 -1 mg group vs control group; þ P < 0.05 -5 mg group vs control group; #P < 0.05 -10 mg group vs control group. 
Discussion
These studies had two major aims: firstly, to determine the acute and chronic effects of central administration of MCH to satiated rats; and, secondly, to identify changes in hypothalamic peptides through which the changes in food intake and body weight induced by chronic administration of MCH may occur. Previous studies have presented conflicting views on the acute effects of MCH on food intake. Some studies have shown that when injected into the brain at low doses MCH inhibits food intake. 10 Other studies have shown increased food intake at higher doses of the peptide. 6 -8 These apparently conflicting results may be due to the dose administered or to differences in the timing and=or site of peptide injection. However, the present results indicate that, when injected into the lateral ventricle at the beginning of the light phase in satiated adult Wistar or Sprague -Dawley rats, MCH acts only to stimulate appetite.
The chronic effects of MCH on food intake and body weight in free-feeding Sprague -Dawley and Wistar rats were also investigated in these studies. Continuous infusion of MCH into the ventricular system increased food intake for 7 -8 days. The increase in food intake during this period was associated with a substantial increase in body weight. This was the expected result, but it disagrees with previous studies that have shown that tolerance to the effects of exogenously administered MCH develops after 5 days of repeated single injections and without a corresponding change in body weight. 6 However, our results clearly show that, when continually infused at relatively low doses, a sustained effect of Figure 3 Neuropeptide gene expression in Wistar and SpragueDawley rats. At the end of the experiment described in Figure 2 the control animals were killed and the hypothalamus removed for the measurement of neuropeptide mRNA expression. RT-PCR experiments were performed with the primers listed in Table 1 to co-amplify GAPDH mRNA and the specific neuropeptide mRNAs shown. Representative RT-PCR analyses with two RNA samples (lanes 1 and 2) are shown for each neuropeptide=GAPDH of Wistar (W.) and Sprague -Dawley (S.D.) rats. The ratio of neuropeptide and GAPDH mRNA signals was determined individually and these normalized values compared between the two rat strains. Data are presented as mean AE SEM from 9 -12 animals per group. For the measurement of neurotensin (NT) mRNA only 4 -6 rats per group were used. Statistics were by unpaired t-test. * P < 0.05 between Wistar and S.D. rats. a At the end of the experiment the rats illustrated in Figure 2 were killed and RNA was extracted from each individual hypothalamus. RT-PCR experiments were performed with primers listed in Table 1 to co-amplify GAPDH mRNA and the specific neuropeptide mRNAs (see Figure 3) . b The ratio of neuropeptide and GAPDH mRNA signals was determined individually for control and MCH-injected rats. These normalized values were compared between the control and MCH groups separately in Wistar and Sprague -Dawley rats. Data are presented as mean AE s.e from 7 -10 animals in each group of rats with controls taken as 100%. *Significant difference (P < 0.05) between control and MCH group.
Administration of melanin-concentrating hormone O Della-Zuana et al MCH on food intake can be obtained for as long as MCH is administered into the brain. Mice lacking MCH have been generated by deletion of the MCH gene and are hypophagic and lean, while transgenic mice overexpressing the MCH gene are hyperphagic with increased body weight. 4, 11 Based upon these observations and our studies with acute and particularly chronic infusions it is tempting to conclude that MCH plays an important physiological role in the stimulation of appetite and body weight. However, this conclusion should be tempered by the fact that knockout of the MCH gene and chronic infusion of the peptide into the ventricles would be expected to modulate the activity of all brain MCH receptors. MCH receptors are widely distributed in the brain and linked to other behaviors in addition to food intake. 20 Therefore, neither the mouse knockout nor the ventricular infusion of MCH may accurately mimic the changes in the endogenous peptide that actually occur in brain to mediate changes in feeding behavior.
Food intake is controlled by a complex interplay between different neural pathways in the hypothalamus. 12 -14 The involvement of MCH with central neurotransmitter pathways was investigated in the present study by determining changes in the mRNA expression level of several neuropeptides after chronic treatment with MCH. The neuropeptides studied were chosen for their known effects on food intake and putative interaction with MCH containing neurons in the brain. 3, 5, 13 Strikingly, baseline expression of the mRNAs encoding for MCH and NPY were markedly different between Sprague -Dawley and Wistar rats. Compared with Wistar rats, the higher expression of these two orexigenic peptides in Sprague -Dawley rats may be related to the relative hyperphagia and propensity of this rat strain to weight gain. 21 After treatment with MCH the only significant change noted was an increase in the expression of NPY in SpragueDawley rats. Elevations in NPY following infusion of MCH may also explain the greater increase in food intake observed after the chronic infusion of MCH in Sprague -Dawley compared to Wistar rats. The consistent pairing of increased NPY and MCH may suggest a functional interaction between these two peptides in the control of food intake in SpragueDawley rats. This possibility was investigated in combination studies which demonstrated consistently additive effects of the two peptides on food intake. Although maximum stimulation of the MCH food intake pathway was obtained at a dose of 5 mg the effects of MCH and NPY remained additive, strongly suggesting that the effects of NPY on food intake are not be mediated thorough the release of MCH. Since 5 mg is also close to a maximum dose of NPY it is also unlikely that the effects of MCH are entirely mediated by NPY. Although the results suggest that each peptide stimulates food intake through an independent pathway this tentative interpretation must await detailed studies with clean and selective NPY and MCH antagonists when they become available. The reason why NPY expression was elevated in the hypothala- Figure 4 Food intake in response to single and combined central injections of MCH and NPY in Sprague -Dawley rats. Peptides were given as single injections or in combinations (injection volume was always 2.5 ml) at the beginning of the light phase. Results expressed as mean AE s.e. from 9 -12 animals in each group. Statistical analysis was determined by one-way analysis of variance of the data at each dose followed by the Student -Neuman -Keuls procedure. At all doses of the peptides studied the combination of MCH and NPY produced a significantly greater increase in food intake than either peptide administered alone. * P < 0.05 comparing the MCH þ NPY group with all other groups. D Change in food intake from control values (g) Administration of melanin-concentrating hormone O Della-Zuana et al mus of these overfeeding rats with increased body weight remains enigmatic. However, it is possible that MCH increases NPY concentrations in the brain of SpragueDawley rats, even if this is not obligatory for the expression of the effect of MCH on food intake. Although only changes in NPY gene expression were observed after treatment of the animals with MCH it is recognized that the control of food intake is mediated through changes in the activity of neuropeptides released in specific hypothalamic regions. 22 In the present studies, gene expression was measured in the whole hypothalamus and so small changes in areas involved in feeding behavior may have been offset in the present studies by opposite changes in other regions. Clearly additional studies investigating the expression of levels of the intact peptides in specific hypothalamic regions are now needed to more clearly define the role of neuropeptides in mediating=and or modulating the actions of MCH on food intake.
In conclusion, the results of this study convincingly demonstrate that MCH is an important stimulator of food intake and weight gain when acutely or chronically administered into the brain and as such is an interesting target for the development of appetite suppressant and antiobesity drugs.
